-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Genting Shinyao announced today that Gosartuzumab has obtained orphan drug designation granted by South Korea’s MFDS, which is used to treat locally unresectable advanced or metastatic triple-negative breasts that have received at least two lines or more of previous treatment.
Triple negative breast cancer (TNBC) is a highly aggressive disease that accounts for approximately 15% of all breast cancer types worldwide.
In recent decades, the incidence of breast cancer in South Korea has been among the highest in the world.
Sacituzumab govitecan-hziy (Gosartuzumab) is a first-of-its-kind antibody-drug conjugate with a target of TROP-2, which is a membrane antigen that is overexpressed in many common epithelial cancers.
Note: The original text has been deleted